Pancreatic Neuroendocrine Tumors in Glucagon Receptor-Deficient Mice

Run Yu,Deepti Dhall,Nicholas N Nissen,Song-Guang Ren,Cuiqi Zhou,Amanda Ewart Toland

doi:10.1371/journal.pone.0023397

Abstract

Inhibition of glucagon signaling causes hyperglucagonemia and pancreatic α cell hyperplasia in mice. We have recently demonstrated that a patient with an inactivating glucagon receptor mutation (P86S) also exhibits hyperglucagonemia and pancreatic α cell hyperplasia but further develops pancreatic neuroendocrine tumors (PNETs). To test the hypothesis that defective glucagon signaling causes PNETs, we studied the pancreata of mice deficient in glucagon receptor (Gcgr−/−) from 2 to 12 months, using WT and heterozygous mice as controls. At 2–3 months, Gcgr−/− mice exhibited normal islet morphology but the islets were mostly composed of α cells. At 5–7 months, dysplastic islets were evident in Gcgr−/− mice but absent in WT or heterozygous controls. At 10–12 months, gross PNETs (≥1 mm) were detected in most Gcgr−/− pancreata and micro-PNETs (<1 mm) were found in all (n = 14), whereas the islet morphology remained normal and no PNETs were found in any WT (n = 10) or heterozygous (n = 25) pancreata. Most PNETs in Gcgr−/− mice were glucagonomas, but some were non-functioning. No tumors predominantly expressed insulin, pancreatic polypeptide, or somatostatin, although some harbored focal aggregates of tumor cells expressing one of those hormones. The PNETs in Gcgr−/− mice were well differentiated and occasionally metastasized to the liver. Menin expression was aberrant in most dysplatic islets and PNETs. Vascular endothelial growth factor (VEGF) was overexpressed in PNET cells and its receptor Flk-1 was found in the abundant blood vessels or blood islands inside the tumors. We conclude that defective glucagon signaling causes PNETs in the Gcgr−/− mice, which may be used as a model of human PNETs. Our results further suggest that completely inhibiting glucagon signaling may not be a safe approach to treat diabetes.

Highlights

The pancreatic a cells are not well understood but have essential functions in normal physiology and diabetes pathogenesis [1,2]
We have recently described for the first time a patient with a novel disease (Mahvash disease) of marked hyperglucagonemia without glucagonoma symptoms, diffuse a cell hyperplasia, and pancreatic neuroendocrine tumors (PNETs) associated with a homozygous inactivating Glucagon signals through its receptor (GCGR) mutation (P86S) [18,19,20]
None of the 48 WT mice died during the observational period (12 months) while 4 of the 111 heterozygous mice (1 postpartum bleeding, 1 large pelvic tumor, and 2 unknown cause) and 3 of the 52 Gcgr2/2 mice (1 gross PNET and 2 unknown cause) died

Summary

Introduction

The pancreatic a cells are not well understood but have essential functions in normal physiology and diabetes pathogenesis [1,2]. The main function of a cells is to secrete glucagon, an important hormone regulating glucose homeostasis. Glucagon signals through its receptor (GCGR), a G protein-coupled receptor, resulting in activation of the stimulatory G protein (Gs) and generation of cAMP [3,4,5]. The main target organ of glucagon is the liver where glucagon stimulates transcription and activity of key enzymes for glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output. Direct inhibition of glucagon signaling, raises safety concerns as it causes a cell hyperplasia, a possible precursor lesion of pancreatic neuroendocrine tumors (PNETs) [8,9,10,11,12,13,14]

Methods

Results

Conclusion